Health
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is finalizing the development plan for the optimal regulatory pathway to approval Allschwil, Switzerland – January 30, 2026Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORLDSymposium™, taking place fr
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry population","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"The company is finalizing the development plan for the optimal regulatory pathway to approval","length":93,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":272,"olType":false},{"type":"text","content":"Allschwil, Switzerland – January 30, 2026Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORLDSymposium™, taking place from February 2-6, 2026.","length":250,"tagName":"p"},{"type":"text","content":"The following two posters will be presented on February 5, 15:30 PST (February 6, 00:30 CET):","length":93,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study (#125, Kiosk 14-B)","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Lucerastat effect on kidney function in patients with Fabry disease: Results from the ongoing open label-extension (OLE) of the phase 3 clinical program (#361. Kiosk 39-B)","length":171,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":336,"olType":false},{"type":"text","content":"The posters present long-term results from the Phase 3 MODIFY study and its open-label extension when ongoing participants had received lucerastat for at least 42 months, with some exceeding six years of continuous therapy. These data provide important insight into the durability of lucerastat’s clinical effects and tole...